TY - GEN
T1 - Independent prognostic significance of minimal residual disease status in chronic lymphocytic leukaemia
AU - Kwok, Marwan Cheng Kuang
AU - Rawstron, Andy C
AU - Varghese, Abraham
AU - Evans, Paul
AU - O'Connor, Sheila
AU - Doughty, Chi
AU - Newton, Darren
AU - Moreton, Paul
AU - Hillmen, Peter
PY - 2014/2
Y1 - 2014/2
N2 - Eradication of minimal residual disease (MRD) is an independent predictor of survival outcome in patients with chronic lymphocytic leukaemia (CLL) receiving fludarabine and cyclophosphamide (FC) or fludarabine, cyclophosphamide, and rituximab (FCR) as first-line treatment. However, the independent prognostic relevance of MRD status in other therapeutic settings is not clear. The goal of this study was to investigate the independent importance of achieving MRD negativity in CLL on progression-free survival (PFS) and overall survival (OS) with different treatments in frontline and relapsed or refractory settings compared with known prognostic markers.
AB - Eradication of minimal residual disease (MRD) is an independent predictor of survival outcome in patients with chronic lymphocytic leukaemia (CLL) receiving fludarabine and cyclophosphamide (FC) or fludarabine, cyclophosphamide, and rituximab (FCR) as first-line treatment. However, the independent prognostic relevance of MRD status in other therapeutic settings is not clear. The goal of this study was to investigate the independent importance of achieving MRD negativity in CLL on progression-free survival (PFS) and overall survival (OS) with different treatments in frontline and relapsed or refractory settings compared with known prognostic markers.
UR - http://dx.doi.org/10.1016/s0140-6736(14)60329-9
U2 - 10.1016/s0140-6736(14)60329-9
DO - 10.1016/s0140-6736(14)60329-9
M3 - Conference contribution
VL - 383
T3 - The Lancet
SP - S66
BT - Lancet
ER -